Science Explorer Back to mapMap
Discussion
Company · San Diego · United States

Fate Therapeutics (United States)

In research, Fate Therapeutics (United States) stands highest in Health Sciences (#15,166 of 16,688 worldwide) and Medicine (#13,553 of 14,558 worldwide), over all time. Relative to its size it is most specialised in Oncology (Oncology is 22.5× its share of world research).

fatetherapeutics.comROR OpenAlex
World rank, 2022-now
#22,131
of 22,385 · #31,997 all time
Rank in United States
#3,289
of 3,332
Research works
263
▼ 5% vs 2018-21
Citations
3.1k
11.7 per fractional work
Top-10% rate
12.4%
all institutions 10.0%
vs its own fields
0.94×
1.00× is exactly expected
Open access
40%
world 40%
International
16%
world 18%
Fate Therapeutics (United States)

What is Fate Therapeutics (United States) known for in research?

The fields where it stands highest, over all time, ranked among every institution above the floor in each field.

FieldWorld rankWhere that sitsTop-10% rateWorks
Health SciencesDomain #15,166 of 16,688 9.9%129
MedicineField #13,553 of 14,558 10.0%126

Each strip is that field's whole ranked pool, with the notch where Fate Therapeutics (United States) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no average mark, because the average differs by field (from about 6% in Dentistry to 21% in Economics).

Which fields of science does Fate Therapeutics (United States) work in?

In 2022-now, 52% of research at Fate Therapeutics (United States) is in Health Sciences, 36% in Life Sciences. Its largest fields are Medicine (51%), Biochemistry, Genetics and Molecular Biology (22%), Immunology and Microbiology (13%). It does 2.4× the world's share of Life Sciences.

Health Sciences: 47 fractional works · 51.6% of its workMedicine: 47 fractional works · 50.6% of its workOncology: 23 fractional works · 25.3% of its workPulmonary and Respiratory Medicine: 3 fractional works · 3.7% of its workRheumatology: 3 fractional works · 3.1% of its workRadiology, Nuclear Medicine and Imaging: 3 fractional works · 2.8% of its workGenetics: 2 fractional works · 2.1% of its workHematology: 2 fractional works · 1.7% of its workPathology and Forensic Medicine: 2 fractional works · 1.7% of its workPhysiology: 1 fractional works · 1.5% of its workSurgery: 1 fractional works · 1.5% of its workNephrology: 1 fractional works · 1.4% of its workPublic Health, Environmental and Occupational Health: 1 fractional works · 0.9% of its workEndocrinology, Diabetes and Metabolism: 1 fractional works · 0.8% of its workNeurology: 1 fractional works · 0.8% of its workEmergency Medicine: 0 fractional works · 0.5% of its workPharmacology: 0 fractional works · 0.4% of its workUrology: 0 fractional works · 0.4% of its workOrthopedics and Sports Medicine: 0 fractional works · 0.3% of its workPsychiatry and Mental health: 0 fractional works · 0.2% of its workEpidemiology: 0 fractional works · 0.2% of its workImmunology and Allergy: 0 fractional works · 0.2% of its workSmaller subfields together: 1 fractional works · 1.3% of its workHealth Professions: 0 fractional works · 0.4% of its workEmergency Medical Services: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.1% of its workNursing: 0 fractional works · 0.2% of its workNutrition and Dietetics: 0 fractional works · 0.2% of its workVeterinary: 0 fractional works · 0.2% of its workDentistry: 0 fractional works · 0.1% of its workLife Sciences: 33 fractional works · 35.7% of its workBiochemistry, Genetics and Molecular Biology: 20 fractional works · 21.6% of its workMolecular Biology: 14 fractional works · 15.7% of its workCancer Research: 2 fractional works · 1.7% of its workGenetics: 1 fractional works · 1.6% of its workCell Biology: 1 fractional works · 1.2% of its workBiotechnology: 1 fractional works · 0.8% of its workBiophysics: 0 fractional works · 0.3% of its workBiochemistry: 0 fractional works · 0.2% of its workImmunology and Microbiology: 12 fractional works · 12.6% of its workImmunology: 12 fractional works · 12.6% of its workNeuroscience: 1 fractional works · 1.2% of its workCellular and Molecular Neuroscience: 1 fractional works · 0.7% of its workSensory Systems: 0 fractional works · 0.3% of its workNeurology: 0 fractional works · 0.3% of its workAgricultural and Biological Sciences: 0 fractional works · 0.2% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 0.1% of its workSocial Sciences: 6 fractional works · 7.0% of its workSocial Sciences: 4 fractional works · 4.1% of its workSociology and Political Science: 2 fractional works · 2.1% of its workPolitical Science and International Relations: 1 fractional works · 1.1% of its workEducation: 0 fractional works · 0.4% of its workHealth: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.2% of its workArts and Humanities: 2 fractional works · 2.0% of its workArcheology: 1 fractional works · 0.7% of its workClassics: 0 fractional works · 0.4% of its workHistory and Philosophy of Science: 0 fractional works · 0.4% of its workReligious studies: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.2% of its workEconomics, Econometrics and Finance: 1 fractional works · 0.8% of its workEconomics and Econometrics: 1 fractional works · 0.8% of its workPsychology: 0 fractional works · 0.2% of its workPhysical Sciences: 5 fractional works · 5.7% of its workEngineering: 2 fractional works · 2.1% of its workBiomedical Engineering: 1 fractional works · 1.2% of its workElectrical and Electronic Engineering: 1 fractional works · 0.9% of its workComputer Science: 1 fractional works · 1.4% of its workArtificial Intelligence: 0 fractional works · 0.5% of its workComputer Vision and Pattern Recognition: 0 fractional works · 0.5% of its workSmaller subfields together: 0 fractional works · 0.3% of its workMaterials Science: 1 fractional works · 1.1% of its workBiomaterials: 0 fractional works · 0.4% of its workMaterials Chemistry: 0 fractional works · 0.4% of its workPolymers and Plastics: 0 fractional works · 0.4% of its workEnvironmental Science: 0 fractional works · 0.5% of its workEcology: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.2% of its workChemistry: 0 fractional works · 0.5% of its workOrganic Chemistry: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.0% of its workEarth and Planetary Sciences: 0 fractional works · 0.1% of its workALL ITS WORKFate Therapeutics(United States)92fractional works, 2022-now
Life Sciences36%Physical Sciences6%Health Sciences52%Social Sciences7%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 20 fields, with their numbers
    1. Medicine4750.6%
    2. Health Professions00.4%
    3. Nursing00.2%
    4. Veterinary00.2%
    5. Dentistry00.1%
    1. Biochemistry, Genetics and Molecular Biology2021.6%
    2. Immunology and Microbiology1212.6%
    3. Neuroscience11.2%
    4. Agricultural and Biological Sciences00.2%
    5. Pharmacology, Toxicology and Pharmaceutics00.1%
    1. Social Sciences44.1%
    2. Arts and Humanities22.0%
    3. Economics, Econometrics and Finance10.8%
    4. Psychology00.2%
    1. Engineering22.1%
    2. Computer Science11.4%
    3. Materials Science11.1%
    4. Environmental Science00.5%
    5. Chemistry00.5%
    6. Earth and Planetary Sciences00.1%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What does Fate Therapeutics (United States) specialise in?

Where its research is concentrated relative to its size: Oncology takes 22.5× the share of its output that it takes of world research.

  1. OncologySubfield · 23.3 works22×
← less than its size predicts1×more →

Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.05× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 4.04× its world share, 20 worksBiochemistry, Geneti…Immunology and Microbiology: 12.51× its world share, 12 worksImmunology and Micro…Neuroscience: 0.77× its world share, 1 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 0.34× its world share, 0 worksPharmacology, Toxico…Chemistry: 0.30× its world share, 0 worksChemistryComputer Science: 0.18× its world share, 1 worksComputer ScienceEarth and Planetary Sciences: 0.06× its world share, 0 worksEarth and Planetary …Engineering: 0.14× its world share, 2 worksEngineeringEnvironmental Science: 0.11× its world share, 0 worksEnvironmental ScienceMaterials Science: 0.31× its world share, 1 worksMaterials ScienceDentistry: 0.30× its world share, 0 worksDentistryHealth Professions: 0.16× its world share, 0 worksHealth ProfessionsMedicine: 2.63× its world share, 47 worksMedicineNursing: 0.45× its world share, 0 worksNursingVeterinary: 1.11× its world share, 0 worksVeterinaryArts and Humanities: 0.69× its world share, 2 worksArts and HumanitiesEconomics, Econometrics and Finance: 0.39× its world share, 1 worksEconomics, Econometr…Psychology: 0.05× its world share, 0 worksPsychologySocial Sciences: 0.32× its world share, 4 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 12.5×. Every wedge is a field page.

All 20 fields, with their numbers
  1. Immunology and Microbiology12.51×12 works
  2. Biochemistry, Genetics and Molecular Biology4.04×20 works
  3. Medicine2.63×47 works
  4. Veterinary1.11×0 works
  5. Neuroscience0.77×1 works
  6. Arts and Humanities0.69×2 works
  7. Nursing0.45×0 works
  8. Economics, Econometrics and Finance0.39×1 works
  9. Pharmacology, Toxicology and Pharmaceutics0.34×0 works
  10. Social Sciences0.32×4 works
  11. Materials Science0.31×1 works
  12. Chemistry0.30×0 works
  13. Dentistry0.30×0 works
  14. Computer Science0.18×1 works
  15. Health Professions0.16×0 works
  16. Engineering0.14×2 works
  17. Environmental Science0.11×0 works
  18. Earth and Planetary Sciences0.06×0 works
  19. Agricultural and Biological Sciences0.05×0 works
  20. Psychology0.05×0 works

Who are the top researchers at Fate Therapeutics (United States)?

Ranked on the quality score, Bahram Bob Valamehr, Ramzey Abujarour and Paul Rogers lead among researchers whose main affiliation is Fate Therapeutics (United States).

  1. 1 Bahram Bob Valamehr United States · #123,322 worldwide 3.6k citations · 158 works
  2. 2 Ramzey Abujarour United States · #264,715 worldwide 3.5k citations · 68 works
  3. 3 Paul Rogers United States · #266,637 worldwide 4.3k citations · 52 works
  4. 4 Alec D. Witty United States · #421,804 worldwide 2.1k citations · 35 works
  5. 5 Ryan Bjordahl United States · #460,032 worldwide 1.7k citations · 86 works
  6. 6 Svetlana Gaidarova United States · #472,833 worldwide 3.8k citations · 66 works
  7. 7 Daniel D. Shoemaker United States · #485,862 worldwide 18k citations · 56 works
  8. 8 Yu‐Waye Chu United States · #540,573 worldwide 2.2k citations · 65 works
  9. 9 Jason R. O'Rourke United States · #554,570 worldwide 2.4k citations · 26 works
  10. 10 John Goulding United States · #563,624 worldwide 2.5k citations · 56 works
All ranked researchers at Fate Therapeutics (United States)

What are the most cited papers from Fate Therapeutics (United States)?

The most cited paper from Fate Therapeutics (United States) is "Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations" (Alexander Edward Dela Cruz Drilon et al., 2018), with 489 citations. Next come "Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies" (412) and "Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential?" (252).

Most cited papers
#PaperReleasedCitations
1 Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations Alexander Edward Dela Cruz Drilon et al. · Cancer Discovery 9 Aug 2018 489
2 Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies David T. Rodgers, Magdalena Mazagova, Eric N. Hampton et al. · Proceedings of the National Academy of Sciences Open access 12 Jan 2016 412
3 Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential? Stephanie K Venn-Watson, Rick Lumpkin, Edward A. Dennis · Scientific Reports Open access 18 May 2020 252
4 iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti–PD-1 therapy Frank M. Cichocki et al. · Science Translational Medicine Open access 4 Nov 2020 250
5 Additional support for schizophrenia linkage on chromosomes 6 and 8: A multicenter study Dieter B. Wildenauer et al. · American Journal of Medical Genetics 127 authors 22 Nov 1996 186
All 60 most cited papers, with filters and sorting

Which keywords describe research at Fate Therapeutics (United States)?

By fractional works in 2022-now, weighted toward what it does more of than the world: Cancer Immunotherapy, Immunotherapy, Tumor Regression, Lymphoma, CAR T Cells, Chimeric Antigen Receptor, Natural Killer Cells and NK Cell Recognition.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Cancer Immunotherapy20▲ 145×3 topics
  2. Immunotherapy20▲ 30×7 topics
  3. Tumor Regression19▲ 184×2 topics
  4. Lymphoma18▲ 125×3 topics
  5. CAR T Cells18▲ 272×1 topic
  6. Chimeric Antigen Receptor18▲ 272×1 topic
  7. NK Cell Recognition6▲ 97×1 topic
  8. Natural Killer Cells6▲ 97×1 topic
  9. Inflammation5▲ 2.5×25 topics
  10. Monoclonal Antibodies5▲ 58×3 topics
  11. Cancer4▲ 3.5×16 topics
  12. Glycosylation3▲ 33×3 topics
  13. Cancer Therapy3▲ 5.7×7 topics
  14. Immunogenicity3▲ 67×3 topics
  15. Therapeutic Antibodies3▲ 41×2 topics
  16. Phosphorylation2▲ 107×2 topics
  17. Tumor Microenvironment2▲ 6.1×7 topics
  18. Antibody Engineering2▲ 48×1 topic
  19. Biopharmaceuticals2▲ 50×2 topics
  20. Cell Cycle Control2▲ 75×2 topics
  21. Fc Receptors2▲ 48×1 topic
  22. Gene Therapy2▲ 13×4 topics
  23. Metabolism2▲ 4.8×5 topics
  24. Transcriptional Regulation2▲ 15×7 topics
  25. Innate Immunity2▲ 7.3×3 topics
  26. Bioanalytical Methods2▲ 117×1 topic
  27. Biosimilars2▲ 117×1 topic
  28. Immunity2▲ 5.7×4 topics
  29. Neurological Disorders2▲ 4.0×5 topics
  30. Cancer Progression2▲ 12×4 topics
  31. Breast Cancer2▲ 8.3×5 topics
  32. Antigen Presentation2▲ 22×2 topics
  33. Cell Signaling2▲ 12×5 topics
  34. Monoclonal Antibody2▲ 36×2 topics
  35. Dendritic Cells2▲ 21×1 topic
  36. Tumor Antigen2▲ 31×1 topic
  37. Genome Engineering2▲ 28×1 topic
  38. RNA-Guided2▲ 28×1 topic
  39. 14-3-3 Proteins2▲ 295×1 topic
  40. cancer development2▲ 295×1 topic

Which research topics does Fate Therapeutics (United States) publish most on?

By volume in 2022-now: CAR-T cell therapy research, Immune Cell Function and Interaction, Monoclonal and Polyclonal Antibodies Research and Biosimilars and Bioanalytical Methods.

CAR-T cell therapy resea…18CAR-T cell therapy research: 18 fractional worksImmune Cell Function and Interaction: 6 fractional worksMonoclonal and Polyclonal Antibodies Research: 2 fractional worksBiosimilars and Bioanalytical Methods: 2 fractional worksImmunotherapy and Immune Responses: 2 fractional worksCRISPR and Genetic Engineering: 2 fractional works14-3-3 protein interactions: 2 fractional worksRenal Diseases and Glomerulopathies: 1 fractional worksPluripotent Stem Cells Research: 1 fractional worksPI3K/AKT/mTOR signaling in cancer: 1 fractional works
OncologyImmunologyRadiology, Nuclear Medicine and ImagingMolecular Biology1 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 CAR-T cell therapy research Oncology 18 works
  2. 2 Immune Cell Function and Interaction Immunology 6 works
  3. 3 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 2 works
  4. 4 Biosimilars and Bioanalytical Methods Immunology 2 works
  5. 5 Immunotherapy and Immune Responses Immunology 2 works
  6. 6 CRISPR and Genetic Engineering Molecular Biology 2 works
  7. 7 14-3-3 protein interactions Molecular Biology 2 works
  8. 8 Renal Diseases and Glomerulopathies Nephrology 1 works
  9. 9 Pluripotent Stem Cells Research Molecular Biology 1 works
  10. 10 PI3K/AKT/mTOR signaling in cancer Molecular Biology 1 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available39.6%not open60.4%

World: 40% of research is openly available.

with international co-authors15.8%domestic only84.2%

World: 18% is written across borders.

How has Fate Therapeutics (United States)'s research output changed?

Output in 2022-2025 was 5% lower than in 2018-2021.

still counting200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Fate Therapeutics (United States) as a percentage of every work published that year, 0.00040% in 2024.

still counting0.00050%0.0010%Fate Therapeutics (United States)0.00044% in 202519801990200020102020

Fractional works of Fate Therapeutics (United States) over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year, against all institutions in the same year.

still counting10%20%Fate Therapeutics (United States)11.5% in 2025all institutions10.0% in 20252020

Of each year's output, the share that reached the world's 10% most cited for its field and year. Peak 15.7% in 2022.

Other research institutions in San Diego

All research institutions in San Diego

Share Fate Therapeutics (United States)'s ranking

Fate Therapeutics (United States) on Science Explorer

A card with Fate Therapeutics (United States)'s standing and the fields it leads in, for a post or a slide. A link to this page previews as the same card.

Download the card

1200 × 630 PNG, sized for social posts, drawn from the latest snapshot.

Badges for a website1Each links back here and updates with every snapshot

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Fate Therapeutics (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.